Table 2.
Demographic characteristics of HIV infections with virological failure in Hefei from 2018 to 2019.
| Variable | Number | % |
|---|---|---|
| Total | 127 | 100.0 |
| Age (years) | ||
| 18–29 | 24 | 18.9 |
| 30–39 | 53 | 41.7 |
| 40–49 | 15 | 11.8 |
| ≥50 | 33 | 26.0 |
| Unknown | 2 | 1.6 |
| Sex | ||
| Male | 109 | 85.8 |
| Female | 16 | 12.6 |
| Unknown | 2 | 1.6 |
| Ethnicity | ||
| Han | 126 | 99.2 |
| Other | 1 | 0.8 |
| Marital status | ||
| Single | 75 | 59.1 |
| Married | 35 | 27.6 |
| Divorced/widowed | 15 | 11.7 |
| Unknown | 2 | 1.6 |
| Route of infection * | ||
| MSM | 72 | 56.7 |
| HET | 49 | 38.6 |
| IDU | 1 | 0.8 |
| Unknown | 5 | 3.9 |
| VL (copies/mL) | ||
| 1000–10,000 | 58 | 45.7 |
| 10,000–50,000 | 41 | 32.3 |
| >50,000 | 28 | 22.0 |
| ART regimen * | ||
| EFV+3TC+TDF | 47 | 37.0 |
| EFV+3TC+AZT | 16 | 12.6 |
| LPV/r+3TC+TDF | 24 | 18.9 |
| LPV/r+3TC+AZT | 19 | 15.0 |
| NVP+3TC+AZT | 12 | 9.4 |
| Other | 9 | 7.1 |
| Sampling time | ||
| 2018 | 59 | 46.5 |
| 2019 | 68 | 53.5 |
* MSM, men who have sex with men; HET, heterosexual; IDU, injecting drug users. EFV, efavirenz; 3TC, lamivudine; TDF, tenofovir disoproxil; AZT, zidovudine; LPV/r, lopinavir/ritonavir; NVP, nevirapine.